VIR BIOTECHNOLOGY INC (VIR) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:VIR • US92764N1028

7.28 USD
+0.09 (+1.25%)
At close: Feb 9, 2026
7.28 USD
0 (0%)
After Hours: 2/9/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to VIR. VIR was compared to 523 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for VIR as it has an excellent financial health rating, but there are worries on the profitability. VIR has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year VIR has reported negative net income.
  • In the past year VIR has reported a negative cash flow from operations.
  • In multiple years VIR reported negative net income over the last 5 years.
  • VIR had negative operating cash flow in 4 of the past 5 years.
VIR Yearly Net Income VS EBIT VS OCF VS FCFVIR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B

1.2 Ratios

  • VIR's Return On Assets of -49.01% is in line compared to the rest of the industry. VIR outperforms 51.63% of its industry peers.
  • VIR's Return On Equity of -62.76% is fine compared to the rest of the industry. VIR outperforms 60.23% of its industry peers.
Industry RankSector Rank
ROA -49.01%
ROE -62.76%
ROIC N/A
ROA(3y)-16.99%
ROA(5y)-11.28%
ROE(3y)-19.74%
ROE(5y)-12.79%
ROIC(3y)N/A
ROIC(5y)N/A
VIR Yearly ROA, ROE, ROICVIR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60 -80

1.3 Margins

  • VIR has a better Gross Margin (95.94%) than 96.18% of its industry peers.
  • VIR's Gross Margin has improved in the last couple of years.
  • The Profit Margin and Operating Margin are not available for VIR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 95.94%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.7%
GM growth 5YN/A
VIR Yearly Profit, Operating, Gross MarginsVIR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • VIR does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for VIR has been increased compared to 1 year ago.
  • VIR has more shares outstanding than it did 5 years ago.
  • VIR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
VIR Yearly Shares OutstandingVIR Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
VIR Yearly Total Debt VS Total AssetsVIR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

2.2 Solvency

  • VIR has an Altman-Z score of -0.12. This is a bad value and indicates that VIR is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of VIR (-0.12) is better than 60.04% of its industry peers.
  • VIR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.12
ROIC/WACCN/A
WACC12.44%
VIR Yearly LT Debt VS Equity VS FCFVIR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B 2B

2.3 Liquidity

  • A Current Ratio of 7.25 indicates that VIR has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 7.25, VIR is in the better half of the industry, outperforming 71.32% of the companies in the same industry.
  • A Quick Ratio of 7.25 indicates that VIR has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 7.25, VIR is in the better half of the industry, outperforming 71.51% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.25
Quick Ratio 7.25
VIR Yearly Current Assets VS Current LiabilitesVIR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • VIR shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 7.91%.
  • VIR shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -78.55%.
  • VIR shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 55.74% yearly.
EPS 1Y (TTM)7.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
Revenue 1Y (TTM)-78.55%
Revenue growth 3Y-59.24%
Revenue growth 5Y55.74%
Sales Q2Q%-89.92%

3.2 Future

  • Based on estimates for the next years, VIR will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.54% on average per year.
  • The Revenue is expected to decrease by -4.29% on average over the next years.
EPS Next Y11.36%
EPS Next 2Y10.66%
EPS Next 3Y10.17%
EPS Next 5Y10.54%
Revenue Next Year-71.89%
Revenue Next 2Y-65.08%
Revenue Next 3Y-34.39%
Revenue Next 5Y-4.29%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
VIR Yearly Revenue VS EstimatesVIR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
VIR Yearly EPS VS EstimatesVIR Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • VIR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year VIR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VIR Price Earnings VS Forward Price EarningsVIR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VIR Per share dataVIR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.66%
EPS Next 3Y10.17%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • VIR does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VIR BIOTECHNOLOGY INC

NASDAQ:VIR (2/9/2026, 8:00:02 PM)

After market: 7.28 0 (0%)

7.28

+0.09 (+1.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05
Earnings (Next)02-19
Inst Owners65.96%
Inst Owner Change-0.65%
Ins Owners1.07%
Ins Owner Change-0.75%
Market Cap1.01B
Revenue(TTM)16.86M
Net Income(TTM)-499.65M
Analysts82.86
Price Target17.09 (134.75%)
Short Float %11.11%
Short Ratio6.23
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-22.59%
Min EPS beat(2)-35.7%
Max EPS beat(2)-9.48%
EPS beat(4)1
Avg EPS beat(4)-8.92%
Min EPS beat(4)-35.7%
Max EPS beat(4)13.76%
EPS beat(8)3
Avg EPS beat(8)-3.11%
EPS beat(12)3
Avg EPS beat(12)-12.91%
EPS beat(16)6
Avg EPS beat(16)-4.4%
Revenue beat(2)0
Avg Revenue beat(2)-71.93%
Min Revenue beat(2)-88.02%
Max Revenue beat(2)-55.84%
Revenue beat(4)1
Avg Revenue beat(4)-39.6%
Min Revenue beat(4)-88.02%
Max Revenue beat(4)50.52%
Revenue beat(8)3
Avg Revenue beat(8)17.29%
Revenue beat(12)4
Avg Revenue beat(12)-3.91%
Revenue beat(16)7
Avg Revenue beat(16)1.61%
PT rev (1m)-2.74%
PT rev (3m)-2.74%
EPS NQ rev (1m)17.61%
EPS NQ rev (3m)31.64%
EPS NY rev (1m)2.33%
EPS NY rev (3m)-2.02%
Revenue NQ rev (1m)1337.38%
Revenue NQ rev (3m)1279.79%
Revenue NY rev (1m)202.48%
Revenue NY rev (3m)74.38%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 60.08
P/FCF N/A
P/OCF N/A
P/B 1.27
P/tB 1.31
EV/EBITDA N/A
EPS(TTM)-3.61
EYN/A
EPS(NY)-2.96
Fwd EYN/A
FCF(TTM)-3.31
FCFYN/A
OCF(TTM)-3.26
OCFYN/A
SpS0.12
BVpS5.72
TBVpS5.54
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -49.01%
ROE -62.76%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 95.94%
FCFM N/A
ROA(3y)-16.99%
ROA(5y)-11.28%
ROE(3y)-19.74%
ROE(5y)-12.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.7%
GM growth 5YN/A
F-Score2
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 59.06%
Cap/Sales 40.87%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.25
Quick Ratio 7.25
Altman-Z -0.12
F-Score2
WACC12.44%
ROIC/WACCN/A
Cap/Depr(3y)387.02%
Cap/Depr(5y)331.46%
Cap/Sales(3y)13.03%
Cap/Sales(5y)9.92%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
EPS Next Y11.36%
EPS Next 2Y10.66%
EPS Next 3Y10.17%
EPS Next 5Y10.54%
Revenue 1Y (TTM)-78.55%
Revenue growth 3Y-59.24%
Revenue growth 5Y55.74%
Sales Q2Q%-89.92%
Revenue Next Year-71.89%
Revenue Next 2Y-65.08%
Revenue Next 3Y-34.39%
Revenue Next 5Y-4.29%
EBIT growth 1Y3.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year17.45%
EBIT Next 3Y8.12%
EBIT Next 5Y7.88%
FCF growth 1Y31.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y28.66%
OCF growth 3YN/A
OCF growth 5YN/A

VIR BIOTECHNOLOGY INC / VIR FAQ

What is the fundamental rating for VIR stock?

ChartMill assigns a fundamental rating of 3 / 10 to VIR.


What is the valuation status of VIR BIOTECHNOLOGY INC (VIR) stock?

ChartMill assigns a valuation rating of 0 / 10 to VIR BIOTECHNOLOGY INC (VIR). This can be considered as Overvalued.


Can you provide the profitability details for VIR BIOTECHNOLOGY INC?

VIR BIOTECHNOLOGY INC (VIR) has a profitability rating of 2 / 10.


Can you provide the financial health for VIR stock?

The financial health rating of VIR BIOTECHNOLOGY INC (VIR) is 7 / 10.